Efficacy and Safety Data With Pembrolizumab/Lenvatinib in LEAP-001 of Endometrial Cancer

Commentary
Video

Christian Marth, MD, PhD, discusses efficacy and safety findings from the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer.

Related Videos
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus
Hye Sook Chon, MD, gynecologic oncologist, Gynecologic Oncology Program, Moffitt Cancer Center
John Paul Diaz, MD
Keiichi Fujiwara, MD, PhD, Saitama Medical University International Medical Center
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Ramez N. Eskander, MD
Abdulrahman Sinno, MD
Amin Nassar, MD
Rebecca L. Porter, MD, PhD
Related Content
OncLive On Air Podcast Recap

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
FDA

FDA Grants Breakthrough Device Designation to At-Home Cervical Cancer Screening Test

May 9th 2024
Article
R. Wendel Naumann, MD

Naumann Discusses Notable Research Efforts in Endometrial Cancer

October 26th 2023
Podcast
R. Wendel Naumann, MD

Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer

May 7th 2024
Article
FDA

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

April 29th 2024
Article